Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit

In contrast to the use in advanced unresectable breast cancer, no positive effects have been proven for the use of neoadjuvant use of pertuzumab in HER2-positive breast cancer, report reviewers. However, more patients discontinue treatment, particularly due to cardiac disorders.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1QkNw0o